AR082453A1 - Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos - Google Patents
Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismosInfo
- Publication number
- AR082453A1 AR082453A1 ARP110101347A ARP110101347A AR082453A1 AR 082453 A1 AR082453 A1 AR 082453A1 AR P110101347 A ARP110101347 A AR P110101347A AR P110101347 A ARP110101347 A AR P110101347A AR 082453 A1 AR082453 A1 AR 082453A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- substituted
- phenyl
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- -1 halo C1-4 alkyl Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical group 0.000 abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 229910052801 chlorine Chemical group 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 abstract 1
- 108091008644 NR2D Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32649110P | 2010-04-21 | 2010-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082453A1 true AR082453A1 (es) | 2012-12-12 |
Family
ID=44010017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101347A AR082453A1 (es) | 2010-04-21 | 2011-04-19 | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8324239B2 (https=) |
| EP (1) | EP2560976B9 (https=) |
| JP (1) | JP5756850B2 (https=) |
| CN (1) | CN103025738B (https=) |
| AR (1) | AR082453A1 (https=) |
| ES (1) | ES2605039T3 (https=) |
| TW (1) | TW201139446A (https=) |
| UY (1) | UY33348A (https=) |
| WO (1) | WO2011131709A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013004655A (es) | 2010-10-26 | 2013-08-27 | Presidio Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
| WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| BR112017023821A2 (pt) | 2015-05-06 | 2018-07-31 | Leidos Biomedical Res Inc | moduladores de k-ras |
| BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
| MX2019013562A (es) * | 2017-05-19 | 2020-08-03 | Nflection Therapeutics Inc | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. |
| WO2019204449A1 (en) * | 2018-04-18 | 2019-10-24 | Theras, Inc. | K-ras modulators with a vinyl sulfone moiety |
| CN108727309B (zh) * | 2018-06-20 | 2023-04-07 | 天津全和诚科技有限责任公司 | 一种3-氧杂环丁烷羧酸的合成方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4383A (en) | 1846-02-10 | Improvement in condensing steam and feeding steam-boilers | ||
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| ATE270326T1 (de) | 1990-04-04 | 2004-07-15 | Chiron Corp | Protease von hepatitis-c-virus |
| DE69434931T2 (de) | 1993-04-02 | 2007-11-22 | Rigel Pharmaceuticals, Inc., South San Francisco | Methode zur selektiven inaktivierung der viralen replication |
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| US5703116A (en) | 1995-04-18 | 1997-12-30 | Geron Corporation | Telomerase Inhibitors |
| US5861267A (en) | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
| EP0859833B1 (en) | 1995-09-27 | 2006-03-01 | Emory University | Recombinant hepatitis c virus rna replicase |
| US5759795A (en) | 1996-03-08 | 1998-06-02 | Schering Corporation | Assay for determining inhibitors of ATPase |
| JP2001514508A (ja) | 1997-03-05 | 2001-09-11 | ユニバーシティー オブ ワシントン | Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法 |
| US6228576B1 (en) | 1997-12-11 | 2001-05-08 | Smithkline Beecham Corporation | Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JPWO2002051849A1 (ja) | 2000-12-26 | 2004-04-22 | 第一製薬株式会社 | Ｃｄｋ４活性阻害剤 |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| EP1560582A4 (en) | 2002-10-09 | 2008-03-12 | Scios Inc | AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE |
| CN1731993A (zh) | 2002-11-01 | 2006-02-08 | 维洛药品公司 | 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法 |
| MXPA05010802A (es) | 2003-04-25 | 2005-12-14 | Univ Cardiff | Compuestos heterociclicos para el uso en el tratamiento de infecciones virales. |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| CA2534649A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
| UY28526A1 (es) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| TW200528459A (en) | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| JP2007529422A (ja) | 2004-01-29 | 2007-10-25 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 抗ウイルス治療 |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| JPWO2005082905A1 (ja) | 2004-02-26 | 2007-08-02 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
| JP4604086B2 (ja) | 2004-05-07 | 2010-12-22 | エグゼリクシス， インコーポレイテッド | Ｒａｆモジュレーターおよびその使用方法 |
| CA2571881A1 (en) | 2004-06-22 | 2006-01-26 | Andreas P. Termin | Heterocyclic derivatives for modulation of calcium channels |
| TW200618800A (en) | 2004-08-03 | 2006-06-16 | Uriach Y Compania S A J | Heterocyclic compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| MX2007004783A (es) | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
| US20070128270A1 (en) | 2005-11-10 | 2007-06-07 | Wyeth | Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| EP2094692B1 (en) | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| US8198311B2 (en) | 2006-11-01 | 2012-06-12 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| CN101687789A (zh) | 2007-02-12 | 2010-03-31 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
| JPWO2008108309A1 (ja) | 2007-03-02 | 2010-06-17 | 協和発酵キリン株式会社 | 縮環ピリジン誘導体 |
| PE20090142A1 (es) | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
| GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
| KR20100016620A (ko) | 2007-04-23 | 2010-02-12 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체 |
| NZ582096A (en) | 2007-06-29 | 2012-05-25 | Gilead Sciences Inc | Antiviral compounds that inhibit hepatitis c virus (hcv) |
| WO2009027732A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | 5-6-bicyclic heteroaromatic compounds with antibacterial activity |
| WO2009041591A1 (ja) | 2007-09-28 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | 縮環ピリジン誘導体 |
| EP2245023B1 (en) | 2008-02-14 | 2011-12-28 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| US8546410B2 (en) | 2008-05-05 | 2013-10-01 | Abbvie Inc. | Heteroaryl-fused macrocyclic pyrimidine derivatives |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8048887B2 (en) | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2011
- 2011-04-19 AR ARP110101347A patent/AR082453A1/es unknown
- 2011-04-19 US US13/089,764 patent/US8324239B2/en active Active
- 2011-04-20 CN CN201180030410.5A patent/CN103025738B/zh not_active Expired - Fee Related
- 2011-04-20 TW TW100113755A patent/TW201139446A/zh unknown
- 2011-04-20 WO PCT/EP2011/056304 patent/WO2011131709A1/en not_active Ceased
- 2011-04-20 EP EP11715244.7A patent/EP2560976B9/en not_active Not-in-force
- 2011-04-20 ES ES11715244.7T patent/ES2605039T3/es active Active
- 2011-04-20 JP JP2013505470A patent/JP5756850B2/ja not_active Expired - Fee Related
- 2011-04-25 UY UY0001033348A patent/UY33348A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP5756850B2 (ja) | 2015-07-29 |
| EP2560976A1 (en) | 2013-02-27 |
| EP2560976B9 (en) | 2017-06-07 |
| JP2013527842A (ja) | 2013-07-04 |
| TW201139446A (en) | 2011-11-16 |
| CN103025738A (zh) | 2013-04-03 |
| ES2605039T3 (es) | 2017-03-10 |
| WO2011131709A1 (en) | 2011-10-27 |
| US8324239B2 (en) | 2012-12-04 |
| CN103025738B (zh) | 2015-08-19 |
| US20120015907A1 (en) | 2012-01-19 |
| UY33348A (es) | 2011-12-01 |
| EP2560976B1 (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082453A1 (es) | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| CY1121231T1 (el) | Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR079455A1 (es) | Composiciones para el crecimiento y/o recrecimiento del pelo | |
| PE20161368A1 (es) | Inhibidores de diacilglicerol aciltranferasa 2 | |
| AR051248A1 (es) | Derivados de 3-arilamino piridina | |
| PE20120814A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20141535A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
| AR082102A1 (es) | Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR078462A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20161323A1 (es) | Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos | |
| AR061792A1 (es) | Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| PE20250558A1 (es) | Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |